The Veterinary Medicines Directorate has opened applications for a G7 Pharmacovigilance Senior Assessor and Reporting Lead, with the notice published on 18 September 2026 and the closing date set for 12 October 2026. In the department’s own description, the post sits in post-authorisation surveillance and is intended to support the continuing assessment of the benefit-risk balance of veterinary medicines used in the UK. (gov.uk) Although framed as a recruitment notice, the post is a useful indicator of where regulatory effort is currently being directed. The VMD’s published responsibilities include monitoring and acting on adverse event reports, authorising products, enforcing the Veterinary Medicines Regulations and advising ministers on veterinary medicines policy. (gov.uk)
The wider policy point is straightforward: most important safety questions are not settled at the point of approval. In guidance on how it monitors animal medicines, the VMD states that once a product is on the market it is used in a far larger and more varied population than in clinical trials, which means rare or slower-developing adverse events may only become visible after authorisation. (gov.uk) That guidance also explains why post-market surveillance matters in practical terms. The VMD says around 30,000 animals would need to be treated to avoid missing at least one very rare event occurring in 1 in 10,000 exposed animals. For policy readers, that is the clearest reason a senior veterinary assessor matters: pharmacovigilance is not an administrative back-office task, but part of the evidence base for whether a medicine’s expected benefits continue to outweigh its risks. (gov.uk)
The legal framework has also become more exacting. The VMD’s legislation guidance states that in Great Britain the Veterinary Medicines Regulations 2013, as amended, govern the manufacture, authorisation, distribution, use and post-authorisation surveillance of veterinary medicines, with the latest Great Britain amendments made in 2024. The same guidance notes that, under the Windsor Framework, separate arrangements apply in Northern Ireland, where EU veterinary medicines law continues to operate alongside parts of the domestic regime. (gov.uk) Within that framework, pharmacovigilance obligations extend beyond obvious safety failures. VMD guidance requires Marketing Authorisation Holders to report adverse events, human exposure reports, suspected lack of efficacy and environmental events, and to do so within 30 calendar days of awareness. Since 17 May 2024, the implementation explainer says the system has moved towards annual Benefit-Risk Reports and signal notifications through the year, replacing the older periodic model for Great Britain. (gov.uk)
The timing of the recruitment is also notable because the reporting system itself has changed during 2026. The VMD launched an online adverse event reporting service for animal owners, veterinary professionals and suitably qualified persons on 20 May 2026, and then introduced its industry pharmacovigilance reporting service for Marketing Authorisation Holders on 10 July 2026. (gov.uk) That sequence supports a reasonable inference about capacity, even though the vacancy notice does not say so directly. As more case reporting, benefit-risk submissions and signal notifications move into digital workflows, the demand for senior clinical assessment and reporting oversight is likely to rise. The July 2026 industry service combines several submission routes in one platform, including benefit-risk reports, sales submissions, signal notifications and XML adverse event reports. (gov.uk)
For regulated firms, the operational message is less about one vacancy and more about compliance expectations. The VMD’s published standards for 2026 to 2027 set targets to validate human, animal and environmental adverse event reports within 30 calendar days, validate Benefit-Risk Reports within 60 days, complete full assessment of those reports within 120 days, and process urgent signal notifications within three working days. (gov.uk) Those timelines place pressure on company systems as well as on the regulator. VMD guidance says each Marketing Authorisation Holder must maintain a pharmacovigilance system overseen by a Qualified Person Responsible for Pharmacovigilance, or QPPV, with visibility over reporting, signal management, benefit-risk evaluation, inspections, training and corrective action. In that context, a senior assessor and reporting lead is part of the machinery that tests whether company systems are producing complete and usable evidence. (gov.uk)
The public-facing side of the regime is broader than many users may assume. The VMD’s reporting guidance says animal owners and veterinary professionals should report suspected adverse events not only when a medicine appears to have caused harm, but also when a product has not worked as expected, has been used off-label, involves an unauthorised product, or has led to exposure in a person, the environment or food-producing animals. (gov.uk) That matters because pharmacovigilance is partly built from field intelligence rather than formal studies alone. GOV.UK states that reports are used by the VMD to help check whether medicines remain safe and continue to work as expected. The same guidance makes clear that if a member of the public reports through the service, they will receive a reference number but not ongoing updates, which underlines that the regulatory value of the report lies in aggregate assessment and signal detection rather than case management for individual reporters. (gov.uk)
Read in that broader context, the vacancy is a small but clear marker of regulatory priorities. The official notice describes the role as continuous monitoring of the efficacy and safety of veterinary medicinal products across their lifecycle, while wider VMD pharmacovigilance guidance links emerging safety concerns to possible regulatory action, including variations, urgent safety restrictions and communication to the public where needed. (gov.uk) For veterinary practices, pharmaceutical companies and policy teams, the significance is practical rather than symbolic. The UK system is moving towards faster reporting, more structured signal handling and greater use of digital submission channels; maintaining the staff base to assess that information is therefore part of regulatory capacity, not a peripheral staffing matter. Applications for the post close on 12 October 2026. (gov.uk)